Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

443
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
443
Inflammatory Response01:28

Inflammatory Response

1.8K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.8K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
The Two-State Receptor Model01:29

The Two-State Receptor Model

1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
1.9K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

2.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of Erectile Dysfunction and Testosterone Deficiency in Testicular Cancer Survivors.

The Journal of urology·2024
Same author

Reply by Authors.

The Journal of urology·2024
Same author

Prostate-Specific Antigen Stratification for Predicting Advanced Prostate Cancer Events in Men Approaching Age Limits for Recommended Screening.

The Journal of urology·2024
Same author

Associations Between Radiation Oncologist Demographic Factors and Segmentation Similarity Benchmarks: Insights From a Crowd-Sourced Challenge Using Bayesian Estimation.

JCO clinical cancer informatics·2024
Same author

Adjuvant Radiation in Resectable Node-Positive Merkel Cell Carcinoma in the Immunotherapy Era: Implications for Future and Ongoing Trials.

Cancers·2023
Same author

Opioid tapering in older cancer survivors does not increase psychiatric or drug hospitalization rates.

Journal of the National Cancer Institute·2023
Same journal

Re: Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25).

Journal of the National Cancer Institute·2026
Same journal

Outcome of metastatic non-rhabdomyosarcoma soft tissue sarcoma in children and young adults treated on children's oncology group ARST0332 trial.

Journal of the National Cancer Institute·2026
Same journal

Pre-diagnosis thyroid biomarkers and breast cancer survival: evidence from a European prospective cohort study.

Journal of the National Cancer Institute·2026
Same journal

NCI's Office of Data Sharing builds momentum to advance cancer research and care.

Journal of the National Cancer Institute·2026
Same journal

RE: Advance care planning impact on caregivers and end-of-life care in advanced cancer.

Journal of the National Cancer Institute·2026
Same journal

Liver cancer risk in the context of today's hormonal contraceptives.

Journal of the National Cancer Institute·2026
See all related articles

Related Experiment Video

Updated: May 29, 2025

High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity
12:02

High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity

Published on: June 2, 2014

12.4K

Response to Oleribe.

Paul Riviere1, James D Murphy1, Lucas K Vitzthum2

  • 1Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92037, United States.

Journal of the National Cancer Institute
|February 1, 2025
PubMed
Summary
This summary is machine-generated.

This study on opioid use in cancer survivors found no evidence of increased persistent opioid use among Black veterans. The data does not support claims of racial disparities in opioid outcomes based on flawed comparative methodology.

More Related Videos

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein
08:04

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

6.8K
Real-time In Vitro Monitoring of Odorant Receptor Activation by an Odorant in the Vapor Phase
09:53

Real-time In Vitro Monitoring of Odorant Receptor Activation by an Odorant in the Vapor Phase

Published on: April 23, 2019

7.0K

Related Experiment Videos

Last Updated: May 29, 2025

High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity
12:02

High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity

Published on: June 2, 2014

12.4K
Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein
08:04

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

6.8K
Real-time In Vitro Monitoring of Odorant Receptor Activation by an Odorant in the Vapor Phase
09:53

Real-time In Vitro Monitoring of Odorant Receptor Activation by an Odorant in the Vapor Phase

Published on: April 23, 2019

7.0K

Area of Science:

  • Oncology
  • Public Health
  • Pharmacology

Background:

  • Persistent opioid use is a significant concern among cancer survivors.
  • Understanding potential racial disparities in opioid outcomes is crucial for equitable care.
  • Previous analyses have suggested racial disparities in opioid use among veteran populations.

Purpose of the Study:

  • To critically evaluate a prior analysis suggesting increased persistent opioid use among Black veterans.
  • To re-examine the data regarding opioid use patterns in cancer survivors, specifically focusing on racial demographics.
  • To address methodological concerns in the assessment of racial disparities in opioid outcomes.

Main Methods:

  • Review and critique of the methodology used in a previous critical appraisal.
  • Analysis of data pertaining to persistent opioid use, abuse, and toxicity.
  • Comparison of opioid use proportions against relevant demographic data.

Main Results:

  • The methodology used in the critical appraisal was found to be flawed.
  • The data does not support the conclusion of increased persistent opioid use among Black veterans.
  • No statistically significant evidence was found to confirm racial disparities in opioid outcomes based on the reviewed data.

Conclusions:

  • The prior conclusion regarding increased persistent opioid use among Black veterans is not supported by the data.
  • Methodological limitations in comparative analyses can lead to inaccurate conclusions about racial disparities.
  • Further rigorous research is needed to accurately assess and address racial disparities in opioid use among cancer survivors.